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ABSTRACT Compounds that can produce potent biological effects in cells encompass a variety of
structural motifs. Many of these compounds share a structural feature that has rarely been noted. It is an
allylic cluster of atoms, a 3-carbon chain with a double bond between two of the atoms and an oxygen
atom at the other end. The oxygen can be in a hydroxyl group, or in an ether or ketal or ester linkage, or
simply a carbonyl form. In the latter case, the linkage is an allylic ketone (ene-one) structure. Nitrogen is
often seen in equivalent forms. Inclusion of at least one allylic moiety appears to be able to turn a modestly
active or inert compound into an effective drug or toxin. Some compounds lack the allylic moiety but
develop one by enzymatic action, usually via cytochrome P-450 enzymes. These metabolites probably
represent the active drug forms. The above concepts seem to be radically simplistic and improbable, but
the evidence supporting them and the explanations for the biological activities are hidden ‘‘in plain view.’’
Comparisons with the pleiotropic activities of the allylic sphingolipid, ceramide, indicate that many allylic
drugs operate by controlling the state of protein phosphorylation, by activating proteases, by generating
reactive oxygen species, by slowing mitochondrial electron transport, or by lowering cellular glutathione
concentrations. Drug Dev Res 69:15–25, 2008 r2008 Wiley-Liss, Inc.
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INTRODUCTION
Medicinal chemists have discovered or designed a
huge number of drugs that while differing greatly in
structure, yet display similar biological activities. In a
few cases, a particular structural fragment appears to
be the primary source of efficacy, but in most cases
there seems to be no rationale for the particular
structure chosen. In many cases a single drug has been
found to attack a variety of disorders or targets, making
the puzzle of design analysis even more curious. The
result, a huge indigestible mass of drug data, cries for a
simplifying integration that may offer a new research
direction.
A few researchers have noted that allylic ketones
are potent inhibitors of cell growth, and thus potential
anticancer drugs. The value of incorporating the
cyclopentenone or cyclopentenedione moiety (Fig. 1)
into drugs has been pointed out [Honn and Marnett,
1985; Santoro et al., 1987; Conti, 2006]. The structural
essence of these allylic ketone fragments (–C=C–
C(=O)–) is seen in many drugs and in some compounds
endogenous to the body. A direct comparison of a non-
allylic ketocyclopentane-containing plant hormone,
methyl jasmonate, with the same compound made into
an allylic ketone by incorporating a double bond in the
D2 position, showed 29 times the growth inhibitory
potency in the latter [Ishi et al., 2004]. In a comparison
of benzylacetone, a non-allylic ketone, with benzalace-
tone (which has the required double bond), the latter
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et al., 1998]. A triple bond was even more effective than
the double bond.
Similar comparisons of curcumin analogues have
also shown the importance of simple allylic ketones,
allylic alcohols, and amines. Curcumin, in its main
tautomeric form, contains an allylic alcohol and an
allylic ketone near each other, each based on a different
double bond. Replacement of the two O’s with the two
N’s of a pyrazole ring increases the water solubility and
also produces a more active drug [Shim, 2004].
Numerous researchers have reported that allylic
ketones bind the major cellular thiol, glutathione
(GSH), by the Michael condensation, producing a thio
ether and eliminating the allylic double bond. This
produces a decrease in cellular GSH, a controller of the
activity of key enzymes. Recently it has been recog-
nized that the drugs can also bind to the CySH thiol
groups in specific proteins, also a substantial effect
[Shiraki at al., 2005; Hamel et al., 2000]. A detailed
study of the reaction with a natural allylic ketone,
15-deoxy-D12,14-prostaglandin J2, showed that only
specific proteins (such as c-Jun) undergo the Michael
condensation [Sánchez-Gómez et al., 2004]. The
double bond in the cyclopentenone ring apparently
represents the preferred condensation site; however,
reduction of this bond still allows condensation with
the protein, apparently with the other allylic double
bond at D12,13, but not to the same extent.
Rapamycin, an anticancer drug containing an
allylic alcohol and an allylic methoxyl moiety, owes its
activity to the allylic 7-methoxy group [Luengo et al.,
1995]. Variants of oleanolic acid, a non-allylic rather
inert triterpenoid, show that adding an allylic N atom









































































Fig. 1. Different types of allylic moieties. In some fragments, the arrows point to the polar allylic atom. Bottom left: a camptothecin variant has
four allylic residues. Bottom right: an allylic ketone metabolite of fenretinide has two (see the cyclohexene ring).
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double bond in ring A) yields active suppressors of
inflammation and inducers of phase 2 cytoprotective
enzymes [Sporn et al., 2007]. Replacement of the
nitrile by an allylic methoxycarbonyl or an extra allylic
ketone, resulted in potent apoptotic activity.
A more general hypothesis has been proposed,
based on the properties of ceramide [Radin, 2003].
This simple, widely distributed sphingolipid amide is
composed of two building blocks, a fatty acid and a
lipoidal amine, the most common being sphingosine
(Fig. 2, left top). The hydroxyl on C-3 of sphingosine is
an allylic alcohol, due to the trans-D4-double bond.
Ceramide (Cer) controls cell growth and proliferation,
generates reactive oxygen species (ROS) in mitochon-
dria and releases mitochondrial proteins, controls
insulin and dendritic cell function, and activates
protein kinases, protein phosphatases [Chalfant et al.,
1999; Pettus et al., 2002], and some proteases. It
inhibits mitochondrial electron flow, modulating opera-
tion of Coenzyme Q activity (ubiquinone, a double
allylic ketone). It also inhibits aromatase [Andrews
et al., 2005], the enzyme that converts androgens to
estrogens and thereby stimulates the conversion of Cer
to glucosylCer (an antiapoptotic sphingolipid) [Shukla
et al., 1992].
Cer induces production of the death-inducing
mitochondrial protein, BNIP3 [Daido, 2004], influ-
ences angiogenesis, Ca21 transport, tubulin polymer-
ization, and many physiological functions. Cer, like
temperature elevation, can induce heat shock protein
ab-crystallin [Chang et al., 1995]. Metabolites of Cer,
such as sphingosine and ganglioside GD3, also control
protein phosphorylation. Various Cer metabolites have
roles in cell physiology, e.g., control of multi-drug
resistance (via MDR1) [Derosa et al., 2007; Gouaze-
Andersson et al., 2007], providing binding sites for
microbes and toxins [Radin, 2006], control of water
homeostasis [Stoll et al., 1980], blood vessel diameter,
apoptosis, and ischemic recovery. Cathepsin D is
stimulated by Cer [Heinrich et al., 2000], while
ceramides stabilize raft domains in cell membranes,
displacing cholesterol and binding various growth-
promoting factors.
The importance of protein phosphate groups is
well established, but the number of phosphoproteins
controlled by Cer and other sphingolipids remains
unknown. Cer affects the phosphorylation state of
proteins such as Akt, Jun, JAK3, Bax, PKCa, PKCz,
RAF-1, KSR, Bcl2, p38 MAPK, Tau, cd25, STAT1/3,
and Rb. These pleiotropic activities of exogenous and
endogenously produced Cer are not seen with
exogenous dihydroCer, which lacks the key allylic
double bond supporting the importance of the allylic
structure. The apoptotic activity of some Cer analogues
(Fig. 2) is independent of the location of the allylic
moiety in Cer. Interchanging the OH and double bond,
so the latter is at D3 and the OH is at C–5, yielded
higher activity [Crawford et al., 2003]. Adding an extra,
conjugated double bond to Cer at D6 enhanced
apoptotic activity [Struckhoff et al., 2004]. Moving
the D4 double bond of Cer into a methylene side chain,
which still maintained the allylic structure, increased
the antiproliferative activity [Lu et al., 2005]. More-
over, the absolute orientation of an allylic OH seems
relatively unimportant, as shown with the C–15 OH in
prostaglandin A2 [Honn and Marnett, 1985]. The allylic
fragment in Cer need not even be in the sphingosine
chain (see Fig. 2, right bottom) [Azuma et al., 2003].
This lack of specificity requirement helps explain why
so many different allylic drugs have similar activity.
Some metabolites of Cer have opposite effects,
stimulating cell growth and countering the influence of
Cer. It is evident that a dynamic balancing process
operates in animals, normally maintaining a healthy
state. The balance between the apoptotic and anti-
apoptotic sphingolipids is controlled by many factors,
such as tumor necrosis factor-a (TNF-a), GSH, fatty
acids, phospholipids, chlorpromazine, and microbial
toxins. Many drugs elevate the level of Cer so it is not
always clear whether the biological effects are due only
to the Cer or to both the drug and Cer. It is also
apparent that some allylic drugs mimic or inhibit the
action of Cer on some proteins.
BRINGING ALLYLIC MOIETIES OUT INTO CLEAR
VIEW
Naturally occurring allylic compounds are widely
distributed, but it is often difficult to recognize the
presence of the allylic moieties. Perhaps the best way to
view one is to look for an isolated double bond or a
series of conjugated double bonds. Then look at the

































Fig. 2. Ceramide (top left) and some analogues that also show good
apoptotic activity.
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is attached to an O or N atom. Conversely, one can look
for an O or N atom, and then count off the closest
chain of three C atoms connected to it. The second and
third atoms should be connected by a double or triple
bond. Figure 1 lists a large number of allylic clusters.
In some drugs, the S atom in a thio ether with an
adjacent propene chain appears to show allylic proper-
ties. Another technique is to look at rings, aliphatic or
heterocyclic. If the ring contains only one or two
double bonds, there may be an allylic O or N on an
adjacent carbon or part of the ring. A hydroxymethyl
group is sometimes attached to the double bond. An
isolated methylene carbon protruding from a ring or
chain is often a clue to an adjacent allylic O or N. In the
case of D2-carboxylic acid esters (–C=C–C(=O)OR),
either O can be considered allylic but the carbonyl O
appears to be more important. A similar question arises
for D2-amides. In N-ethylmaleimide (Fig. 1), the
popular reagent for Michael condensation with thiols,
the carbonyl O appears more important.
Searching for the hidden allylic moiety in many
synthetic drugs can be confusing because one or both
of the C atoms in an allylic double bond may be
attached to an O or N atom. These ‘‘extra’’ polar atoms
offer extra H-bonding sites that probably improve the
protein fit and also affect the reactivity of the allylic O
or N. They certainly improve water-solubility. Consider,
for example, the ease with which the OH of indole-3-
carbinol (an allylic alcohol) dissociates to form a
carbocation. In this case, one of the double bond
carbons is attached to the N atom. A nearby
trifluoromethyl group also appears to increase activity
[Motohashi et al., 2001]. A tertiary amine near an allylic
C–O can enhance the ability of a drug to condense with
endogenous thiols [Pati et al., 2007a].
Quinones are double allylic ketones. The allylic O
can also be present in an OH, or ether, or ketal, or ester
linkage, or a simple carbonyl group. Other compounds
contain an allylic N (amine or imine linkage) instead of
an O. Identifying the allylic N in drugs/compounds
bearing multi-nitrogen, basic moieties (e.g., imidazoles,
pyrazoles) calls for clear eyes.
Not infrequently, two different allylic oxygens
share the same double bond, or two double bonds
share the same O. Some structures that are nonplanar
are especially difficult to analyze in a 2-dimensional
representation.
Allylic compounds occur in a very wide range of
structures; often (in drugs) there is more than one
allylic moiety in each molecule. See the variant
campothecin structure (Fig. 1), with three allylic Os
and an allylic N. Multi-allylic drugs can probably react
with more than one kind of protein, adding to their
versatility. Allylic moieties occur in sphingolipids,
prostanoids, polyunsaturated fatty acids, vitamins,
coenzymes, steroids, porphyrins, and various metabo-
lites. In plants, molds, and bacteria, allylic compounds
appear to operate as biological defense or offense
weapons.
HOW ALLYLIC COMPOUNDS PRODUCE THEIR
SPECIAL EFFECTS
Control of Protein Size and Phosphorylation State
Many of the biological effects of allylic alcohols
can be attributed to the reactivity of the C–O bond,
which is relatively easily broken to yield a transient free
radical or a carbocation. This can happen even with
allylic esters, ethers, and (probably) ketals. The cation
can condense with a variety of anions, such as a
phosphate derivative. Moreover, the original anion can
return in the original or isomeric form. The double
bond in the carbocation readily migrates (the ‘‘allylic
rearrangement’’), so the condensation with an anion
might take place on an adjacent C atom. An example of
double bond movement is seen in an allylic ester,
dimethylallylpyrophosphate, formed during the course
of cholesterol biosynthesis.
The same carbocation intermediate formed from
Cer and related sphingolipids has been proposed to
explain why they activate or stimulate protein kinases,
protein phosphatases, and proteases [Radin, 2004]. In
the case of kinases, this hypothesis suggests that the
terminal phosphate residue of ATP displaces the allylic
OH from enzyme-bound Cer and is then hydrolyzed at
the other ester link to yield ADP and (transiently) Cer-
3-phosphate. The latter high-energy allylic phosphate
group is then transferred to a hydroxy amino acid
moiety in a protein, forming a phosphoprotein and Cer.
The latter is then ready for a new cycle. This cycle can
also operate in reverse fashion, with a phosphoprotein
forming a phosphate diester with a molecule of Cer
that functions in the active site of a phosphatase. The
site of hydrolysis is then between the phosphate and
protein, yielding the dephosphorylated protein and
transient Cer-3-phosphate. The latter is then hydro-
lyzed to Pi and Cer, ready for the next cycle. Similar
transfers of anion peptides with proteases, such as
cathepsin D may be explained the same way. Thus,
these important enzymes appear to use a sphingolipid
as a bound coenzyme. Since the enzymes function to
some extent even without addition of Cer, they
apparently exist in part as apoenzymes, allowing local
levels of Cer to control their activities. Many drugs
containing allylic alcohol residues elicit changes in
kinase activity or phosphoprotein levels. Some may act
as Cer antagonists in these enzymes (e.g., okadaic acid,
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an allylic alcohol, inhibits protein phosphatase, block-
ing activation by Cer and producing cancer).
Enzymes that control phosphate linkages in DNA
and RNA also respond to Cer and allylic drugs.
Telomerase, which protects DNA, is inhibited by Cer
and allylic drugs (e.g., paclitaxel, etoposide) [Ogretmen
et al., 2001]. RNA polymerase is also inhibited by allylic
drugs with widely differing structures, e.g., rifampin,
streptolydigin, sorangicin A, thiolutin, holomycin, and
corallopyronin A [O’Neill et al., 2000]. Some of these
compounds contain five allylic groups.
Interference With Mitochondrial Energy and
Integrity
Several allylic ketones interfere with the opera-
tion of ubiquinone, the mitochondrial double allylic
ketone essential for respiration. Ubiquinone constantly
cycles through reduction to a free radical, ubisemiqui-
none, is reduced further to the non-allylic hydroqui-
none form, then back again. Cer, which is not an allylic
ketone, also interferes with ubiquinone operation,
probably via enzymatic oxidation of the allylic OH to
an allylic ketone via a free radical intermediate. Also in
the respiratory chain is the electron carrier NADPH, in
which the C=O of the nicotinamide moiety is allylic
with respect to the adjacent double bond in the ring.
NADPH oxidase generates ROS, so interference with a
suitable allylic compound can generate or reduce ROS.
The cholesterol-reducing statins slow the ubiqui-
none synthesis from hydroxymethylglutaryl CoA, thus
augmenting the potency of anti-ubiquinone drugs.
Some statins are also allylic (cerivastatin, atorvastatin,
pravastatin, fluvastatin) and may act to produce
apoptosis [Kaneta et al., 2003]. Statins also influence
Cer levels by reducing the concentration of cholesterol,
which exists in part as a stabilizing complex with
sphingomyelin. Reduction in cholesterol makes sphin-
gomyelin more available to hydrolase activity, thus
elevating Cer.
Cer is attacked by isolated or in situ mitochon-
dria, producing ROS and mitochondrial degeneration,
with production of cytochrome c and other enzymes. It
is likely that mitochondria oxidize the allylic OH in Cer
to form 3-ketoCer, an allylic ketone, which is the actual
inhibitor [Radin, 2001a]. Supporting this hypothesis is
the finding that ketoCer is more apoptotic than Cer
[Azuma et al., 2007]. It is also possible that the free
radical intermediate in Cer oxidation is the primary
inhibitor. KetoCer may also be formed to some extent
by direct oxidation by allylic ketone drugs, via a
quinone reductase exchange reaction. Drugs that
produce ROS also lower GSH levels, thus liberating
sphingomyelinase from its inhibited state. Since Cer
itself causes an increase in mitochondrial ROS
production, even more Cer is formed from sphingo-
myelin, ultimately leading to cytotoxic effects by the
Cer.
Reaction of Allylic Ketones With Cellular Thiol
Groups
Allylic ketones undergo Michael reactions, the
condensation on the double bond with biological thiols
(e.g., glutathione, cysteine) and reactive amines. This
reaction explains the frequent observation that allylic
ketone drugs lower the cellular level of thiols and thus
control the activity of many enzymes. It is important
that GSH inhibits several enzymes that control the
tissue level of Cer and its metabolites. A major example
mentioned above is neutral Mg21-stimulated sphingo-
myelinase, which hydrolyzes sphingomyelin to Cer 1
phosphocholine but is held in check by GSH. This
effect is especially important in cancer cells, which
protect themselves with elevated GSH concentrations.
Adducts of allylic ketone drugs with GSH and
protein-linked CySH have been isolated and identified,
but have not been extensively characterized. Drugs
containing a catechol-like structure are typically
metabolized to o-quinones that crosslink protein chains
via nearby CySH residues. Unfortunately, such thiol
condensation products are probably antigenic, provok-
ing the allergic reactions that are so common in drug
therapy. This may call for the use of immunosuppres-
sants like FTY720, a sphingosine-like drug. KetoCer
can be expected to react like other allylic ketones,
probably binding to protein CySH moieties.
This condensation may explain some unexpected
effects, such as the report that fenretinide (4-HPR)
treatment of DU145 cells produced a large increase in
dihydroCer but not in Cer [Zheng et al., 2006]. Most
analyses of Cer content have relied on methods that do
not distinguish between Cer and dihydroCer, but a
mass spectrometer was used in this instance. Thus, the
possibility was raised that dihydroCer can show
biological activity in some situations. However, it is
likely that fenretinide acts by stimulating the produc-
tion of ROS [Morales et al., 2005], which means
sphingomyelin hydrolysis will yield Cer plus some
dihydroCer (dihydrosphingosine is a minor component
of all the sphingolipid families). According to the allylic
hypotheses, Cer will undergo oxidation to ketoCer, and
a large portion of the allylic ketone form will condense
with protein and thus be lost to the analytical
procedure. The dihydroCer can accumulate tempora-
rily but will ultimately undergo desaturation or
hydrolysis. It is also possible that the cells used in the
study by Zheng et al. preferentially hydrolyze Cer
faster than dihydroCer.
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Using mass spectrometry to better understand
sphingolipid effects, shows that the fatty acid chain
length in Cer plays an important part [Karahatay et al.,
2007]. The rate of sphingosine acylation varies some-
what with the different fatty acids [Morell and Radin,
1970]. Incidentally, this article shows that it is possible
to separate Cer from dihydroCer by thin-layer
chromatography with borate-impregnated silica gel.
An immunoassay specific for Cer offers another
method for specific analysis [Kawase et al., 2002].
Other sources of information are Obeid et al. [1993],
Hannun [1996], Brodesser et al. [2003], Woodcock
[2006], Modrak et al. [2006], Maccioni [2007], Hoetzl
et al. [2007], Bieberich [2004] and papers by Hannun
and colleagues. An important review of the alkylation
reaction describes unexpected features that need
consideration in designing allylic ketones [Pati et al.,
2007a].
Pore Formation in Mitochondria
Cer also has an unexpected function: the forma-
tion of mitochondrial pores [Siskind et al., 2006]. If
sufficient Cer is added to mitochondria, the lipid
assembles into hollow cylinders in the outer mem-
brane, allowing small molecules (cytochrome c, pro-
caspases, heat shock proteins) to leak out of the
mitochondria and initiate mitochondrial breakdown
and apoptosis. DihydroCer does not do this, and the
fatty acid chain length is unimportant, suggesting that
the allylic properties of Cer are involved in the
assembly (and function?) of the channels. Apparently
the polar ends of the Cer molecules face the inside of
the channels, forming a cylinder of allylic alcohol
moieties. This leads me to wonder if these allylic
hydroxyls actively transfer phosphate moieties through
the mitochondrial membranes (see discussion above of
Cer as a coenzyme). This might enable the transfer of
ATP (and linked Na1 or K1?) by a sort of ‘‘bucket
brigade’’ process with stepwise movement from one
Cer OH to the adjacent one.
BIOACTIVATION OF ‘‘ALMOST ALLYLIC’’ DRUGS
Exceptions to the ‘‘allylic hypothesis’’ certainly
exist, so other modes of drug action are operational.
However, some non-allylic compounds are pro-allylics,
converted in the body to allylics, which are probably
the active forms. There are oxygenases (P-450 en-
zymes) that hydroxylate many compounds on a C atom
next to a C=C moiety (often near or in a branched
methyl group), thus creating an allylic fragment. This is
seen with fenretinide, which is hydroxylated on its
cyclohexene ring (Fig. 1, bottom right) [Villani et al.,
2006]. The resultant allylic alcohol is subsequently
oxidized to an allylic ketone that is more effective than
the original drug. Vitamin D3 is similarly activated by
hydroxylation on the hydroxycyclohexane group. The
activities of these oxygenases vary considerably be-
tween individuals, as does the rapidity with which they
are induced. This may explains why there is so much
variability in patient response to drugs and why many
promising non-allylic drugs fall by the wayside late in
testing. If such drugs were offered in the allylic version
instead, dosages could be lowered, which might reduce
the problem of toxic side effects.
Conversely, desaturases can produce an allylic
double bond next to a –C–O– moiety. This is an
essential reaction in the case of dihydroceramide,
which is made from the basic sphingolipid (3-keto-2-
amino-1-octadecanol) by reduction and fatty acylation.
The pyrrolidine ring in indoline is desaturated by
cytochrome P450 to form indole, and 3-substituted
indoles (e.g., 3-methylindole) are dehydrogenated to
form a reactive electrophilic intermediate that reacts
with GSH and thiols [Sun and Yost, 2008].
A common method for producing allylic struc-
tures is the oxidation of two phenolic groups on the
same ring to form a p- or o-quinone. In many
polyphenols, there is at least one methyl ether that
can be oxidatively demethylated and then oxidized.
This is often seen in antioxidants, which become
quinones when they act to protect cells. A similar
oxidation appears to occur with o-diphenols (catechols)
that are bound in ether linkage to the same methylene
C. One example is paroxetine, a selective serotonin
reuptake inhibitor, in which a complex series of
reactions take place at the ether site [Zhao et al.,
2007]. Each of the two allylic ketone groups forms the
expected Michael sulfide link with GSH, followed by
an unusual conversion of the glycylcysteine moiety of
GSH to an allylic imino N ring. Thus, even the final
product is allylic. Some paroxetine binds to tissues,
presumably by a Michael reaction with protein thiols,
including those on p450, which is itself inactivated. It is
not surprising that paroxetine can also produce
apoptosis in cancer cells, apparently due to the o-
quinone moiety, independently of its action on 5HT
[Schuster et al., 2007]. A typical study of allylic ketones,
especially adjacent allylic ketones, showed tight binding
of an allylic toxin, aflatoxin M1, to milk proteins
[Barbiroli et al., 2007]. g-Tocopherol is also metabo-
lized to a quinone that can produce apoptosis and
condense with GSH and protein thiols [Cornwell et al.,
2003].
Etoposide, itself not an allylic drug, is metabo-
lized this way. The oxidation appears to go through a
semiquinone radical intermediate, as in normal ubi-
quinone functioning. Similar quinone formation occurs
with hydroquinone rings, which form p-quinones.
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Doxorubicin, which has a p-quinone ring adjacent to a
hydroquinone ring, may become oxidized to two
adjacent quinone rings, probably a very toxic product
that may limit the usefulness of this anticancer drug.
With suitable connections between two phenyl rings,
each containing a single OH, several conjugated double
bonds will form together with two carbonyl
oxygens, which probably improves reactivity with
thiols, since more sites are available for the Michael
condensation.
Polyunsaturated fatty acids, characterized by
methylene-interrupted double bonds, are oxidized by
oxygen to allylic peroxides, which can be reduced
enzymatically to allylic alcohols. These are split to some
extent by ROS to form the reactive allylic aldehyde,
4-hydroxy-2-nonenal. Such steps are part of arachido-
nate conversion to the HETEs and prostanoids.
Some phenyl-containing drugs, e.g., tamoxifen,
are oxidized to phenols, which are in turn oxidized
further to quinones as discussed above. A detailed
description of such bioactivations appears in Dowers
et al. [2006], which describes three different allylic
tamoxifen metabolites and a carbocation. Other phe-
nylated drugs can be metabolized to an epoxy
derivative, which is then opened by epoxide hydrolase
to form a catechol ring, which then is oxidized to an o-
quinone. In the case of flavone-8-acetic acid, the
resultant catechol derivative [Pham et al., 2007] can be
expected to form an o-quinone in which the double
bonds are conjugated with the adjacent flavone pyrone
group. This additional allylic ketone group should
enhance the activity.
As mentioned above, a double bond can move
over one C atom closer to an OH, to yield an allylic
alcohol. This kind of shift is seen in an early step in the
biosynthesis of squalene. Here, the double bond in
isopentenyl pyrophosphate is shifted (reversibly) one C
closer to the OH, to form dimethylallyl pyrophosphate,
an allylic pyrophosphate ester. Prenyl transferase then
shifts the same double bond of a second molecule of
isopentenyl pyrophosphate over one C atom to
accommodate condensation with the dimethylallyl
carbocation formed by dissociation of the pyropho-
sphate moiety. This forms geranyl pyrophosphate, then
repeats the condensation to add another unit, forming
farnesyl pyrophosphate. Allylic alcohols from both
esters can produce apoptosis in cancer cells. The same
shift occurs in pregnenolone, an ‘‘almost allylic’’ sterol
that forms progesterone, an allylic ketone. In the
conversion of prostaglandin J2 to 15-deoxy-D12-PGJ2,
dehydration of the allylic OH forms an extra
double bond and moves the adjacent one over by one
position. Several allylic drugs also contain an ‘‘almost
allylic’’ OH.
The structures of most drug metabolites are
unknown or difficult to track down, but one can quickly
obtain a clue by testing the effectiveness of a drug after
adding a P-450 inhibitor or a thiol, e.g., N-acetyl-
CySH. Searching for a protein-bound metabolite of an
allylic ketone drug can be done with a radioactive drug
or mass spectrometry.
PARTIAL LIST OF ALLYLIC AND PRO-ALLYLIC
DRUGS
The claim ‘‘many drugs are allylic’’ can be tested
by simply looking at various drug and metabolite
structures. Space limitations prevent showing them
here, but my previous papers on the subject show
some [Radin, 2003, 2007a,b]. Only names are shown in
Table 1. You may be surprised to recognize some of the
names.
It is significant that the use of combinatorial
chemistry to create a library of paclitaxel analogues has
produced a new compound that enhances the effec-
tiveness of paclitaxel on multi-drug resistant cells
[Edwards, 2007]. Containing three allylic oxygens, its
IC50 value was 31 nM. A scan of 10,000 compounds for
anticancer activity yielded an allylic ketone (DBPT 5
5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-
thiazolidin) [Teraishi et al., 2005]. The use of structural
bioinformatics to design protein kinase inhibitors
led to an irreversibly binding allylic ketone
[Cohen et al., 2005]. A computerized search for
inhibitors of Stat3, based on the structure of the
protein, examined 429,000 potential small molecules
and yielded a 4-ring p-quinone, STA-21 [Song et al.,
2005].
DISCUSSION
While there is considerable evidence to support
the allylic hypothesis, additional experiments are
needed to make it more practical. Comparing an allylic
drug with the same compound in which the double
bond has been hydrogenated might strengthen the
hypothesis. How does the loss of the double bond
affect the activity, metabolism, and side reactions? The
non-allylic version might be rapidly converted biologi-
cally to the allylic version, or it might interfere with the
action of a natural allylic metabolite or drug, by
competing for binding to the same enzyme active site.
However, binding of the drug to the enzyme might
require simultaneous formation of the allylic carboca-
tion or condensation with a specific enzyme thiol, so
the non-allylic imposter drug might have little affinity
for the active site. For example, binding might require
bringing an allylic OH close to the strongly basic
guanidine group of an Arg in the active site.
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More information is needed about the properties
of allylic amines and imines; are they really much like
the corresponding oxygen compounds? Perhaps they
must first undergo N-dealkylation and oxidation to
allylic aldehydes. In drugs containing an allylic double
bond shared by a C=O and an allylic tertiary N, the
amine group is readily displaced by an OH [Pati et al.,
2007b]. High anticancer potency was observed with a
simple related allylic structure in which an amino N
and a carbonyl O were activated by two different
double bonds (3,5-distyryl-4-piperidone) [Pati et al.,
2007a].
Are the oxygen and nitrogen atoms often seen on
the double bonds of commercial drugs really useful for
binding or functioning, or is their main value an
increase in water-solubility? The author’s experience
with the solubility problem is that crude, uncontrolled
suspensions, made by injecting an alcoholic solution of
drug into growth or assay medium, yields misleading
data [Radin, 2007b]. It seems wise to compare only
well-dispersed drugs, especially in animal testing. The
alternative dosing technique, gavage, must introduce a
strong stress response. In human use, dispersed drugs
circulate safely in the blood for longer periods and also
react preferentially with the proteins that most strongly
bind them. This enhances their specificity and reduces
toxic side effects.
Is Cer (or another allylic sphingolipid) an
activator of all protein kinases or just primary ones,
which then act on many other kinases? If it acts in all of
them, a column containing Cer bound to the support
particles [Heinrich et al., 2000] might be useful for
kinase purification. How many proteases contain Cer?
Mass spectrometric analysis of Cer-treated proteins
might answer this question. Since there are hundreds
of protein kinases, it is possible that different (allylic
TABLE 1. Allylic and Pro-allylic Drugs
Acetaminophen, acolbifene, actinomycin D, aflatoxins, AGN193198. aldosterone, 17-allylamino-17-demethoxygeldanomycin, amiodarone,
amphidinolides, amphotericin B, anandamide, annonacin, antipyrine, apigenin, arzoxifene, ascididemin, atorvastatin, atovaquone,
atractyloside, aureothin, avermectin
Bengamide A, bimatoprost, bleomycin, bongkrekic acid, briaranes, brinzolamide, bruceantin, brucine, bufadienolide, bullatacin
Calcipotriol, calicheamicin, calotropin and other cardenolides, calyculin A, camptothecin, capsaicin metabolite M8, carbenoxolone, CDDO-Im
(2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide), cefdinir, cerivastatin, chalcones, chlordiazepoxide, cimetidine (MI 2300),
cinnamedrine MI 2320), cinnamaldehyde, ciprofloxacin, clobetasol, clozapine, colchicine, concanamycin, corallopyronin A, cortexolone,
crocin, crotonyloxymethyl-trihydroxy-cyclohexenone, cryptophycins, curcumin, 2-cyclohexen-1-ones and 1-ols, 2-cyclopentene-1-ones and
1-ols, cyclovalone, cytarabine, cytocholasin D, cytotorienin A
Daidzein, dajisentan, dantrolene, dasitinib, daunorubicin, 2-deacetoxyaustrotropicatine, 2-deacetoxytaxinine J, dehydrozingerone,
7-deoxynarciclasine, desonide, dexamethasone, digoxin, 5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin, docetaxel,
doxorubicin, doxycycline, 15-deoxy-D12,14-prostaglandin (PGJ2)
Efavirenz, emodin, epithilone, eplerenone, esculetin, etoposide
F11334, farnesol, fenretinide, ferulic acid, flavopiridol, floxuridine, fluvastatin, fodosine, folinic acid (leucovorin), forskolin, fostriecin,
FR901464, fenpyroximate
Gambogic acid, gangliosides, ganoderol, gefarnate, gefitinib, gemcitabine, genestein, geraniol, gimatecan, gossypol, guanacatepene A, GW5810
Herbimycin A, holomycin, 14b-hydroxybaccatin, 7-hydroxycholesterol, hydroxyjasmonic acid, 4-hydroxynonenal, hymenialdisine
Idabenone, illudins, imidazo[2,1-b]thiazoles and 2,3-dihydroimidazo[2,1-b]thiazoles connected by means of a methylene bridge to CoQ,
indole-3-carbinol, irinotecan
Kaempferol, khafrefungin
Landomycin, lapachol, lapatinib, lavendamycin, LAQ824, linalool, luteolin, LY 294002
Manumycin A, manzamine A, marinomycin A, masoprocol, meayamycin, menadione, meridine, 5-methyltetrahydrofolic acid, methymycin,
mitomycin D, mitoxantrone, monocrotaline, morin, morphine, MPTP (methylphenyldihydropyridine), mupirocin, myxothiazol
Navelbine, nelfinavir metabolites M1 and M3, nifedipine, nobiletin, nocodazole, NSC 668602, NSC606985, 618296, 314622
Oltipraz (a thio analog), ortataxel, OSU-A9 (a derivative of 3-OH-methyl indole), ouabain, 200-oxovoruscharin
Pachyclavulide, paclitaxel, 6-paradol, paroxetine, parthenolide, PD98059, pectenotoxin-1, pentostatin, D-perillyl alcohol, phenoxodiol,
pheophorbide a, phorbol diesters, phytol, piceatannol, picromycin, piericidin, pimecrolimus, plakorstatin, plaunatol, plitidepsin, porphyrins,
pravastatin, prostacyclin, pyrantel, pyridaben
Quassinoids, quercetin
Radicocol, raloxifene, rapamycin, resiniferatoxin, resveratrol, retinoic acid, rhizoxin, rifampin, rofecoxib (Vioxx), rotenone, rottlerin, ryanodine
Salutaridine, salvicine, scyphostatin, seco-temsirolimus, seocalcitol, sorangicin A, SPD-304, squamocin, STA 21 (NSC #628869), stigmatellin,
streptolydigin, strychnine, SU11652, subcoriacin, sungucine, sunitinib, swinholide A
Tacrolimus, TAK-242, tamoxifen, tautomycin, tedanolide C, temzolimide, tetracycline, D9-tetrahydrocannabinol, thapsigargin,
thenoyltrifluoroacetone, thiolutin, tibolone and its D4 isomer, tilosin, topotecan, triamcinolone, trichostatin A, trichothecenes, troxacitabine,
tryptolide




alcohol) drugs differ in their specificity as Cer agonists/
antagonists.
If the allylic structure is indeed desirable in
potential drug designs, limiting new designs to allylic
compounds might save a good deal of work. From a
preparative point of view, it might be worth using
available non-allylic versions and convert them to allylic
analogues with a mixture of microbial P-450 s.
Allylic drugs not only typically contain regions
that seem to be superfluous, but also regions that are
relatively reactive (oxirane rings, aldehydes, peroxides).
These may provoke unnecessary side effects. They may
react covalently with proteins that side-track the drugs
before they reach their target, forming allergenic
products. In the author’s view, it would be wise to
avoid unusual groups and instead incorporate multiple
allylic fragments, some of which involve nitrogen. Free
OH groups tend to waste drugs, via sulfation or
glucuronidation, so pro-drug versions, i.e., methyl
ethers [Walle, 2007] or esters, may be more effective.
In general, researchers who test simple allylic com-
pounds in animals have been struck by their low
toxicity and lack of interference by multi-drug resis-
tance.
Since Cer elevation by drugs seems to play a
major role in their utility, it is worth examining the
mechanisms by which Cer is elevated. This is done by
using the different inhibitors available for controlling
the multiple routes of Cer biosynthesis. Some drugs
stimulate de novo synthesis from palmitic acid and
serine, some stimulate hydrolysis of sphingomyelin
by acid or neutral sphingomyelinase, and some inhibit
the loss of Cer by preventing its conversion to
glycosphingolipids, or hydrolysis by ceramidases [Liu
et al., 2008]. Thus, the ideal therapeutic approach
would be the use of a mixture of drugs, one for each of
the reactions [Radin, 2001b]. This approach also
reduces the compensating induction of enzymes that
normally occurs when a single drug inhibits only one
enzyme. As Modrak et al. [2004] have pointed out,
sphingomyelin is a simple nontoxic source of Cer that
belongs in any drug cocktail. A Cer-like analogue that is
more efficient than Cer would also improve the
effectiveness of a cocktail. Even when administered
alone, in the diet, sphingomyelin and Cer show
anticancer activity.
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